Kanada - enska - Health Canada

medican pharma incorporated - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

Kanada - enska - Health Canada

dominion pharmacal - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

Bandaríkin - enska - NLM (National Library of Medicine)

remedyrepack inc. - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 25 mg - sertraline hydrochloride tablets are indicated for the treatment of the following [see clinical studies (14)] : - major depressive disorder (mdd) - obsessive-compulsive disorder (ocd) - panic disorder (pd) - posttraumatic stress disorder (ptsd) - social anxiety disorder (sad) - premenstrual dysphoric disorder (pmdd) sertraline hydrochloride tablets are contraindicated in patients: - taking, or within 14 days of stopping, maois, (including the maois linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions (5.2), drug interactions (7.1)] . - taking pimozide [see drug interactions (7.1)] . - with known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [see adverse reactions (6.1, 6.2)]. risk summary overall, available published epidemiologic studies of pregnant women exposed to sertraline in the first trimester suggest no difference in major birth defect risk compared to the background rate for major birth defects in compar

Bandaríkin - enska - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline 50 mg - sertraline hydrochloride is indicated for the treatment of the following [see clinical studies (14)] : - major depressive disorder (mdd) - obsessive-compulsive disorder (ocd) - panic disorder (pd) - posttraumatic stress disorder (ptsd) - social anxiety disorder (sad) - premenstrual dysphoric disorder (pmdd) sertraline hydrochloride is contraindicated in patients: - taking, or within 14 days of stopping, maois, (including the maois linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions (5.2), drug interactions (7.1)] . - taking pimozide [see drug interactions (7.1)] . - with known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [see adverse reactions (6.1, 6.2)]. in addition to the contraindications for all sertraline hydrochloride formulations listed above, sertraline hydrochloride oral solution is contraindicated in patients: - taking disulfiram. sertraline hydrochloride oral solution contains alcohol, and concomi

Bandaríkin - enska - NLM (National Library of Medicine)

mylan specialty l.p. - selegiline (unii: 2k1v7gp655) (selegiline - unii:2k1v7gp655) - selegiline 6 mg in 24 h - emsam (selegiline transdermal system) is a monoamine oxidase inhibitor (maoi) indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . the available data on emsam use in pregnant women are not sufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. in animal embryo-fetal development studies, transdermal administration of selegiline to rats and rabbits at doses up to 60 and 64 times the maximum recommended human dose (mrhd) respectively, produced slight increases in malformations in both rats and rabbits, and decreased fetal weight, delayed ossification, and embryo-fetal post-implantation loss in rats. most of these effects were seen at the high dose in both rats and rabbits. these effects were not seen at 8 times and 16 times the mrhd in rats and rabbits, respectively. in a pre-natal and post-natal development study, transdermal administration of selegiline in rats at doses 8, 24, and 60 times mrhd produced a decrease in pup weight an

Bandaríkin - enska - NLM (National Library of Medicine)

sandoz inc - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 2.5 mg - dexmethylphenidate hydrochloride is indicated for the treatment of attention deficit hyperactivity disorder (adhd) [see clinical studies (14)] . pregnancy category c in studies conducted in rats and rabbits, dexmethylphenidate was administered orally at doses of up to 20 and 100 mg/kg/day, respectively, during the period of organogenesis. no evidence of teratogenic activity was found in either the rat or rabbit study; however, delayed fetal skeletal ossification was observed at the highest dose level in rats. when dexmethylphenidate was administered to rats throughout pregnancy and lactation at doses of up to 20 mg/kg/day, postweaning body weight gain was decreased in male offspring at the highest dose, but no other effects on postnatal development were observed. at the highest doses tested, plasma levels (aucs) of dexmethylphenidate in pregnant rats and rabbits were approximately 5 and 1 times, respectively, those in adults dosed with the maximum recommended human dose (mrhd) of 20 mg/day. racemic methylphen

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - selegiline hydrochloride - oral tablet - 10mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - selegiline hydrochloride - oral tablet - 10mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - selegiline hydrochloride - oral tablet - 10mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - selegiline hydrochloride - oral tablet - 10mg